Information date: 30 September 2026 — China's Advertising Law bans superlatives such as 'national level', 'the best' or 'No.1' and requires pre-publication review approval for categories including drugs, medical devices, health food, formula food, education and financial investment products. Internet ads must be identifiable as ads, allow one-click closing, and paid ranking must be labelled '广告'. Regulators may fine up to five times the advertising fee, or a fixed range where fees cannot be verified. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
China's Advertising Law bans superlatives such as 'national level', 'the best' or 'No.1' and requires pre-publication review approval for categories including drugs, medical devices, health food, formula food, education and financial investment products. Internet ads must be identifiable as ads, allow one-click closing, and paid ranking must be labelled '广告'. Regulators may fine up to five times the advertising fee, or a fixed range where fees cannot be verified.
Applies to websites, apps, mini-programs, live commerce, influencer posts and cross-border landing pages shown in mainland China. Confirm first: which entity is the legal advertiser, whether the product falls in a pre-review category, whether a celebrity or KOL endorsement is used, whether user data drives targeting, and what qualification documents each platform demands before placement.
How the effect reaches operations
Enforcement turns on whether content counts as commercial promotion, so brand-owned accounts, product detail pages and live scripts can be treated as advertising even without media spend. Category rules decide whether an approval number is required — missing it is a procedural breach — while wording and unproven efficacy claims trigger a substantive breach, and the two are assessed independently.
Typical misjudgements: translating global creative without rewording, assuming owned social accounts are not advertising, citing unverifiable figures or test results, running unlabelled influencer videos, and health or finance claims that imply guaranteed outcomes. A competitor or consumer complaint can open an investigation quickly and freeze the campaign.
For “China Advertising Compliance Guide: Internet Ad Filings, Claims and Penalty Triggers for Foreign Brands”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
If the category needs pre-review, obtain the approval number before any placement. For general consumer goods, clear superlatives and unproven claims and assemble the evidence file (test reports, patents, sales-data sources) before launch. Add specialist legal review for health, education, financial, children's or medical products.
Implementation checklist
- Map every live asset, from site page to KOL script, to one category rule.
- Delete superlatives and replace each efficacy claim with a documentable source.
- Keep approval numbers, evidence files and takedown logs in one auditable folder.
- Assign one decision owner, one implementation owner and a dated review point for “China Advertising Compliance Guide: Internet Ad Filings, Claims and Penalty Triggers for Foreign Brands”.
- For “China Advertising Compliance Guide: Internet Ad Filings, Claims and Penalty Triggers for Foreign Brands”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “China Advertising Compliance Guide: Internet Ad Filings, Claims and Penalty Triggers for Foreign Brands”.
Evidence and review
For “China Advertising Compliance Guide: Internet Ad Filings, Claims and Penalty Triggers for Foreign Brands”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Map every live asset, from site page to KOL script, to one category rule.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Delete superlatives and replace each efficacy claim with a documentable source.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Keep approval numbers, evidence files and takedown logs in one auditable folder.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Limits of the conclusion
This guide is general information, not legal advice; advertising classification, review requirements and penalty exposure depend on the specific product, wording and media and should be confirmed with qualified PRC counsel.
